|Day Low/High||40.48 / 41.09|
|52 Wk Low/High||31.43 / 48.25|
Marek Fuchs, senior contributing analyst at TheStreet, talks proportion on Glaxo.
Simon Dingemans, CFO of GlaxoSmithKline, discusses the company's bid for Human Genome, Obamacare and the company's growing emerging-market business.
Adrian Adams, CEO of Auxilium, discusses the company's breakthrough with Xiaflex, as well as recent news surrounding its drug Testim.
A look at the day's most searched trends on the Web, including GlaxoSmithKline's intentions to take its bid for Human Genome Sciences hostile.
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
Aviat, Capstone and Axcelis are high-reward/high-risk plays for under $2.50.
A look at the day's most searched topics on the Web, including the European Union's approval of Johnson & Johnson's $21.3 billion takeover of Synthes.
Biotech is changing, so here's how to invest amid the industry's new gold rush.
If you need to live on investment income, bonds and CDs are not enough -- you need dividends.
The damage to a big drug's approval odds is much less than is presently priced into LGND.